Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Peregrine Pharmaceuticals, Inc. Shares Tumbled

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Peregrine Pharmaceuticals (NASDAQ: PPHM  ) , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer, dipped as much as 11% after reporting its third-quarter earnings results.

So what: For the quarter, Peregrine reported total revenue of $3.89 million, a 44% decline from the year-ago period. Peregrine currently generates all of its revenue from its biomanufacturing subsidiary, Avid Bioservices, which experienced lumpiness in the timing of service orders this quarter. Net loss for the quarter widened to $9.72 million, or $0.06 per share, from $4.91 million, or $0.04 per share in the year-ago period. By comparison, Wall Street had expected $5.1 million in revenue and a $0.06-per-share loss, meaning Peregrine missed on the top line and met estimates with its loss.

Now what: Today's move seems less oriented with Peregrine's earnings report, since earnings reports are often non-events for primarily clinical-stage biotechs, and more of a retracement of its huge surge on Wednesday after announcing that it'd be presenting in two upcoming Keystone Symposia conferences

Instead of focusing on earnings, what investors should really have their eyes on is the phase 3 trial for bavituximab, its second-line non-small cell lung cancer immunotherapy treatment. The mechanism of action is quite unique, and it delivered a better-than-doubling of median overall survival in phase 2 studies. However, those same phase 2 studies were marred by foul-ups at a third-party contractor. Its phase 3 SUNRISE trial will therefore go a long way to validating the effectiveness of bavituximab. If successful, Peregrine could have plenty of upside, but the odds are heavily stacked against small-cap biotech stocks developing cancer drugs.

Peregrine has soared this year, but even it may have difficulty keeping pace with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (2) | Recommend This Article (7)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2868463, ~/Articles/ArticleHandler.aspx, 9/2/2015 1:08:13 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,237.03 178.68 1.11%
S&P 500 1,933.14 19.29 1.01%
NASD 4,689.29 53.19 1.15%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/2/2015 12:50 PM
PPHM $1.19 Up +0.04 +3.48%
Peregrine Pharmace… CAPS Rating: **